An intraperitoneally administered pentapeptide protects against Aβ1-42 induced neuronal excitation in vivo

G. Juhász, A. Márki, Gabriella Vass, L. Fülöp, D. Budai, B. Penke, G. Falkay, Viktor Szegedi

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

The underlying cause of Alzheimer's disease (AD) is thought to be the accumulation and aggregation of a misfolded protein, amyloid-β (Aβ). A promising strategy against AD is the application of protective, peptide-based neuroprotective agents that selectively bind to Aβ. We recently described a pentapeptide, LPYFDa, which recognizes Aβ-{1-42} and protects neurons against the toxic effects of aggregated Aβ-{1-42} both in vitro and in vivo. Our previous work indicated that the in vivo ejection of fibrillar Aβ-{1-42} into the hippocampal CA1 region resulted in a massive increase in the NMDA-evoked neuronal firing rate. Our current aim was to study whether intraperitoneally administered LPYFDa is capable of protecting against the synaptotoxic action of fibrillar Aβ-{1-42} administered by iontophoresis. Our investigations of the in vivo biodistribution of tritium-labelled LPYFDa and single-unit electrophysiology revealed that LPYFDa readily crosses the blood-brain barrier, and protects the synapses against the excitatory action of fibrillar Aβ-{1-42} in a relatively wide temporal window in rat. This pentapeptide may serve as a lead compound for the design of novel drug candidates for the prevention of AD.

Original languageEnglish
Pages (from-to)189-196
Number of pages8
JournalJournal of Alzheimer's Disease
Volume16
Issue number1
DOIs
Publication statusPublished - 2009

Fingerprint

Alzheimer Disease
Hippocampal CA1 Region
Serum Amyloid A Protein
Iontophoresis
Tritium
Poisons
Electrophysiology
Drug Design
Neuroprotective Agents
N-Methylaspartate
Blood-Brain Barrier
Synapses
Neurons
Peptides
leucyl-prolyl-tyrosyl-phenylalanyl-aspartamide
Lead
In Vitro Techniques

Keywords

  • Alzheimer's disease
  • Hippocampus
  • Neuroprotection
  • NMDA
  • Protective pentapeptide
  • Single-unit

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Geriatrics and Gerontology
  • Clinical Psychology

Cite this

@article{9a2007a5baa6495da76e3b7d86a93b13,
title = "An intraperitoneally administered pentapeptide protects against Aβ1-42 induced neuronal excitation in vivo",
abstract = "The underlying cause of Alzheimer's disease (AD) is thought to be the accumulation and aggregation of a misfolded protein, amyloid-β (Aβ). A promising strategy against AD is the application of protective, peptide-based neuroprotective agents that selectively bind to Aβ. We recently described a pentapeptide, LPYFDa, which recognizes Aβ-{1-42} and protects neurons against the toxic effects of aggregated Aβ-{1-42} both in vitro and in vivo. Our previous work indicated that the in vivo ejection of fibrillar Aβ-{1-42} into the hippocampal CA1 region resulted in a massive increase in the NMDA-evoked neuronal firing rate. Our current aim was to study whether intraperitoneally administered LPYFDa is capable of protecting against the synaptotoxic action of fibrillar Aβ-{1-42} administered by iontophoresis. Our investigations of the in vivo biodistribution of tritium-labelled LPYFDa and single-unit electrophysiology revealed that LPYFDa readily crosses the blood-brain barrier, and protects the synapses against the excitatory action of fibrillar Aβ-{1-42} in a relatively wide temporal window in rat. This pentapeptide may serve as a lead compound for the design of novel drug candidates for the prevention of AD.",
keywords = "Alzheimer's disease, Hippocampus, Neuroprotection, NMDA, Protective pentapeptide, Single-unit",
author = "G. Juh{\'a}sz and A. M{\'a}rki and Gabriella Vass and L. F{\"u}l{\"o}p and D. Budai and B. Penke and G. Falkay and Viktor Szegedi",
year = "2009",
doi = "10.3233/JAD-2009-0947",
language = "English",
volume = "16",
pages = "189--196",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "1",

}

TY - JOUR

T1 - An intraperitoneally administered pentapeptide protects against Aβ1-42 induced neuronal excitation in vivo

AU - Juhász, G.

AU - Márki, A.

AU - Vass, Gabriella

AU - Fülöp, L.

AU - Budai, D.

AU - Penke, B.

AU - Falkay, G.

AU - Szegedi, Viktor

PY - 2009

Y1 - 2009

N2 - The underlying cause of Alzheimer's disease (AD) is thought to be the accumulation and aggregation of a misfolded protein, amyloid-β (Aβ). A promising strategy against AD is the application of protective, peptide-based neuroprotective agents that selectively bind to Aβ. We recently described a pentapeptide, LPYFDa, which recognizes Aβ-{1-42} and protects neurons against the toxic effects of aggregated Aβ-{1-42} both in vitro and in vivo. Our previous work indicated that the in vivo ejection of fibrillar Aβ-{1-42} into the hippocampal CA1 region resulted in a massive increase in the NMDA-evoked neuronal firing rate. Our current aim was to study whether intraperitoneally administered LPYFDa is capable of protecting against the synaptotoxic action of fibrillar Aβ-{1-42} administered by iontophoresis. Our investigations of the in vivo biodistribution of tritium-labelled LPYFDa and single-unit electrophysiology revealed that LPYFDa readily crosses the blood-brain barrier, and protects the synapses against the excitatory action of fibrillar Aβ-{1-42} in a relatively wide temporal window in rat. This pentapeptide may serve as a lead compound for the design of novel drug candidates for the prevention of AD.

AB - The underlying cause of Alzheimer's disease (AD) is thought to be the accumulation and aggregation of a misfolded protein, amyloid-β (Aβ). A promising strategy against AD is the application of protective, peptide-based neuroprotective agents that selectively bind to Aβ. We recently described a pentapeptide, LPYFDa, which recognizes Aβ-{1-42} and protects neurons against the toxic effects of aggregated Aβ-{1-42} both in vitro and in vivo. Our previous work indicated that the in vivo ejection of fibrillar Aβ-{1-42} into the hippocampal CA1 region resulted in a massive increase in the NMDA-evoked neuronal firing rate. Our current aim was to study whether intraperitoneally administered LPYFDa is capable of protecting against the synaptotoxic action of fibrillar Aβ-{1-42} administered by iontophoresis. Our investigations of the in vivo biodistribution of tritium-labelled LPYFDa and single-unit electrophysiology revealed that LPYFDa readily crosses the blood-brain barrier, and protects the synapses against the excitatory action of fibrillar Aβ-{1-42} in a relatively wide temporal window in rat. This pentapeptide may serve as a lead compound for the design of novel drug candidates for the prevention of AD.

KW - Alzheimer's disease

KW - Hippocampus

KW - Neuroprotection

KW - NMDA

KW - Protective pentapeptide

KW - Single-unit

UR - http://www.scopus.com/inward/record.url?scp=58849153581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58849153581&partnerID=8YFLogxK

U2 - 10.3233/JAD-2009-0947

DO - 10.3233/JAD-2009-0947

M3 - Article

C2 - 19158435

AN - SCOPUS:58849153581

VL - 16

SP - 189

EP - 196

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 1

ER -